Integrated BioTherapeutic Vaccines works closely with a team of highly experienced scientists at its parent company, IBT, a Board of Directors composed of seasoned experts in vaccine manufacturing and development, and a Scientific Advisory Board comprising many of the leading clinicians and basic science experts in the field of S. aureus immunology and clinical management.

Dr. Aman is a molecular immunologist and corporate executive with over 30 years of experience in the field of immunology, microbiology, and vaccine and immunotherapeutics development for infectious diseases. Dr. Aman founded Integrated BioTherapetics and grew the business, not a clinical-stage company, and raised over $100M in non-dilutive funding. He graduated from the school of Pharmacy at the University of Frankfurt in 1990. Dr. Aman later went on to complete his Ph.D. in molecular immunology at Johannes Wolfgang University in Mainz, Germany and continued his research at NIH and the University of Virginia. He then built his independent research program at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) as a Principal Investigator on the development of vaccines for bacterial toxins such as staphylococcal and B. anthracis toxins as well as viral hemorrhagic fever viruses. Dr. Aman has published over 120 papers ranging from basic research in hematology, signal transduction, to vaccine and antibody discovery for infectious diseases in international scientific journals.

Dr. Nabors is an accomplished biopharmaceutical executive with 25 years of industry experience, and a track record for achieving results at small, medium, and large biopharma companies, with emphasis on vaccines and antibody products. He has broad experience in biopharmaceutical product development from pre-clinical stages through Phase 3 for pediatric, adult, travelers, and biodefense markets. Dr. Nabors has served in the capacity of a strategic leader with a focus on managing projects to timeline and budget to facilitate meeting business goals. His experience in advanced development of biological products has led to a great deal of interaction with the FDA to move products forward into clinical development. He has a demonstrated ability to lead Research and Development functions through effective technical management and winning government grants and contracts. Dr. Nabors has prior work experience at DynPort Vaccine Company, The National Biological Threat Characterization Center, Emergent BioSolutions, Antex Biologics, and Sanofi Pasteur. Dr. Nabors earned a BA in Biology from Wake Forest University and a Ph.D. in Immunology from the University of Georgia.